Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.

Jiong Hu, Zhixiang Shen, Gualin Sun, S.-j. Chen, Z.-y. Wang, Zhu ChenPubMed 1999

Abstract

Through this retrospective study with long-term follow-up, some conclusions can be drawn: 1) Low-dose ATRA is as effective as the standard dose in terms of survival; 2) Initial and peak levels of WBC count during induction therapy are associated with survival; 3) A combination of chemotherapy and ATRA is better than chemotherapy or ATRA alone as postremission therapy; 4) Patients with the long form of PML-RAR alpha tend to have a more favorable OS but not RFS when compared with patients with the short form; 5) Persistent negative RT-PCR in remission is associated with favorable RFS and OS; 6) As2O3 is an effective agent for relapsed patients.
BibTeX
@inproceedings{hu1999long,
  author = {Jiong Hu and Zhixiang Shen and Gualin Sun and S.-J. Chen and Z.-Y. Wang and Zhu Chen},
  title = {{Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.}},
  booktitle = {PubMed},
  year = {1999},
}

Loading related content...

Figure